Kura Oncology, Inc.
Kura Oncology, Inc. is a U.S.-based biopharmaceutical company focused on precision medicines for cancer, with a pipeline built around small-molecule therapies that target cancer signaling pathways. The company evolved from a research-stage developer into a commercial-stage oncology business after FDA approval of ziftomenib, marketed as KOMZIFTI, for relapsed or refractory NPM1-mutated AML.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved and marketed cancer therapy sold in the United States under the KOMZIFTI brand.
Investigational small-molecule programs targeting AML, GIST and other solid tumors.
Upfront, milestone and service revenue from the Kyowa Kirin partnership.
Products
Reported · share of revenue- Collaboration Revenue96.8 %
- Products3.2 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Kura sells KOMZIFTI through specialty distributors and specialty pharmacies in the United States, which then supply pharmacies, health care providers and patients. Its broader economic customers are oncology clinicians, academic and community cancer centers, and payors that determine access and reimbursement for the drug. Collaboration revenue is driven by Kyowa Kirin under the license and clinical supply agreements.
They purchase KOMZIFTI in the U.S. and resell it to providers and patients, making them the direct commercial channel.
Hematologists and oncologists choose whether to use KOMZIFTI or trial combinations in AML and other cancers.
Commercial and government payors determine coverage, prior authorization and patient access, which directly affects adoption.
The collaboration partner provides funding, services and commercial support under the license agreement.
Academic and community sites enroll patients in ziftomenib and other pipeline studies to advance approvals.
Strategy
Kura’s strategy is to build KOMZIFTI into the anchor commercial product while expanding ziftomenib across the AML treatment continuum through combination trials and registrational studies. At the same time, it is using the Kyowa Kirin partnership to support development funding and commercialization execution, while advancing next-generation menin inhibitors and other pipeline assets to broaden the long-term franchise.
The approved product is the first source of product revenue and the base for future oncology franchise growth.
Frontline AML is a larger market than relapsed/refractory disease and could materially expand the addressable patient pool.
Additional indications reduce dependence on a single asset and create optionality if AML competition intensifies.
The company remains cash-consuming and needs capital to fund trials, launch activities and manufacturing scale-up.
Geography
Kura is headquartered in the United States and generates product revenue from U.S. sales of KOMZIFTI. Its development footprint is broader, with patent filings and clinical or regulatory activity across the U.S., Europe, China, Japan and other foreign jurisdictions. Geography matters mainly through U.S. commercialization, global intellectual property protection and the location of clinical development and partnering activity.
Risks
Kura remains highly dependent on ziftomenib, so clinical, regulatory or commercial setbacks could materially impair the business. The company also faces intense competition in oncology, reimbursement pressure, launch execution risk and ongoing financing needs because it is still funding a large development pipeline and a new commercial product.
- Dependence on ziftomenib successImpact: HighLikelihood: High
The company’s value creation is concentrated in one lead asset across multiple indications.
Exposure: AML and future ziftomenib indications
- Clinical and regulatory failureImpact: HighLikelihood: High
Product candidates must succeed in registrational trials and obtain FDA approval before commercialization.
Exposure - Competitive pressure in oncologyImpact: HighLikelihood: High
Large pharma and biotech competitors may launch faster, be safer or more effective, reducing market share.
Exposure: AML and targeted oncology markets
- Financing riskImpact: HighLikelihood: High
The company has a history of operating losses and needs substantial funding for trials and commercialization.
Exposure: Corporate liquidity and pipeline funding
- Reimbursement and access riskImpact: MediumLikelihood: Medium
Coverage decisions and prior authorization can slow adoption of a newly launched specialty drug.
Exposure: U.S. KOMZIFTI sales
Accounting
Judgemental itemsKOMZIFTI revenue is reduced by trade discounts, allowances, co-pay support and payor rebates.
Impact: Affects reported product revenue and gross-to-net deductions
Kyowa Kirin payments depend on identifying performance obligations and timing of services.
Impact: Can create uneven quarterly revenue recognition
R&D expense depends on estimates for site costs, patient enrollment and vendor invoices.
Impact: Can shift expense recognition between periods
As a new product launch, returns, inventory and distribution-related estimates may evolve quickly.
Impact: May affect margins and near-term earnings volatility
Similar listed companies
Publicly listed companies with a comparable business focus.
Incyte Corporation
INCY · Services-Commercial Physical & Biological Research
Incyte is a U.S.-based biopharmaceutical company that discovers, develops, and commercializes proprietary medicines.
OnKure Therapeutics, Inc.
OKUR · Pharmaceutical Preparations
Kymera Therapeutics, Inc.
KYMR · Biological Products, (No Diagnostic Substances)
Karyopharm Therapeutics Inc.
KPTI · Pharmaceutical Preparations
Cogent Biosciences, Inc.
COGT · Pharmaceutical Preparations
Cardiff Oncology, Inc.
CRDF · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026